Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial

• Published in: Hepatology international 2014-10, Vol.8 (4), p.517-526
• Main Authors: Shiffman, Mitchell L., Cheinquer, Hugo, Berg, Christoph P., Berg, Thomas, de Figueiredo-Mendes, Cláudio, Dore, Gregory J., Ferraz, Maria Lúcia, Mendes-Corrêa, Maria Cássia, Lima, Maria Patelli, Parise, Edison R., Rios, Alma Minerva Perez, Reuter, Tania, Sanyal, Arun J., Shafran, Stephen D., Hohmann, Marc, Tatsch, Fernando, Bakalos, George, Zeuzem, Stefan
• Format: Article
• Language: English
• Subjects: Colorectal Surgery; Hepatitis C virus; Hepatology; Medicine; Medicine & Public Health; Original Article; Surgery
• ISSN: 1936-0533; 1936-0541
• DOI: 10.1007/s12072-014-9555-3

Background and aims The combination of pegylated interferon alfa/ribavirin will likely remain the treatment of choice for HCV genotype 2/3 patients in financially constrained countries for the foreseeable future. Patients with poor on-treatment response may benefit from treatment extension. This study examined the effect of 48 versus 24 weeks of peginterferon alfa-2a/ribavirin on the sustained virological response (SVR) in patients with HCV genotype 2/3 who did not achieve rapid virological response (RVR). Methods N-CORE was a multicentre, randomised, phase III study. HCV genotype 2/3 patients receiving peginterferon alfa-2a/ribavirin without a rapid but with an early virological response were randomised at week 24 to stop treatment (Arm A) or continue to 48 weeks (Arm B). The primary efficacy endpoint was SVR. Results Two hundred thirty-five patients were enrolled. End of treatment response was similar in both treatment arms. SVR24 rates were not significantly greater in the extended treatment arm compared with the standard 24-week treatment in either the intention-to-treat or the per-protocol populations (61 vs. 52 %, p  = 0.1934 and 63 vs. 52 %, p  = 0.1461, respectively). Serious adverse events occurred more frequently in patients receiving extended treatment duration (12 %) versus 24-week therapy (4 %). Conclusions It is unclear whether the extension of peginterferon alfa-2a/ribavirin treatment may benefit HCV genotype 2/3 patients who do not achieve RVR. The study was stopped early because recruitment was slower than anticipated, and this may have limited the statistical impact of these findings.